Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

 

Philochem AG (a company of the Philogen group) announces Board of Appeal decision on Philochem’s Patent on Production of Encoded Chemical Libraries

More details

Philogen fornisce un aggiornamento sull’analisi ad interim prevista dallo studio di Fase III FIBROSARC che valuta Onfekafusp alfa (L19TNF) in pazienti con Sarcoma dei tessuti molli, in stato avanzato o metastatico, in prima linea.

FIBROSARC (NCT04650984) è uno studio di Fase III che valuta Onfekafusp alfa (L19TNF, noto anche come Fibromun) in combinazione con doxorubicina rispetto al solo...

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy...

Philogen to attend the ESMO TAT congress in Paris on February 26-28, 2024

Prof. Dr. Giuseppe Curigliano, on behalf of Philogen, is giving a presentation about the Phase I DODEKA study on February 26th, entitled “Phase I dose-escalation trial...

Philogen to attend the Immunotherapy of Cancer Conference (ITOC) in Munich on March 21-23, 2024.

Prof. Dario Neri, PhD, (CEO and CSO of Philogen) is giving a presentation entitled “Immunocytokines”. Follow the link here for more details

Philogen to attend the Immuno-Oncology Summit Europe in London on April 23-25, 2024.

Follow the link here for more details

Philogen to attend the Chemical Biology conference at Novo Nordisk on June 8-9, 2024.

Philogen introduce la piattaforma per il Whistleblowing (Direttiva EU 2019/1937)

Philogen S.p.A. adotta un processo di gestione delle segnalazioni di illeciti riguardanti la Società in linea con le previsioni normative introdotte dal D.lgs. 10 marzo...

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

See more details

Philochem AG (a company of the Philogen group) announces the completion of central radiolabeling activities for the therapeutic use of OncoFAP-23

See more details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions